Acadia Pharmaceuticals Inc (NASDAQ:ACAD) does about 2.13M shares in volume on a normal day but saw 1231007 shares change hands in the recent trading day. The company now has a market cap of 3.75B USD. Its current market price is $22.41, marking a decrease of -0.31% compared to the previous close of $22.48. The 52 week high reached by this stock is $25.23 whilst the lowest price level in 52 weeks is $13.40. The script in recent trading has seen the stock touch a high of $32 and a low of $20.
16 analysts observing the Acadia Pharmaceuticals Inc (ACAD) stock have set the 12-month price targets for the company’s shares at between $20 and $32. The consensus objective for the share price is $27.79, suggesting that the stock has a potential upside of 19.36% over the period. The median price target is 6.62% away from the current levels at $24.
FactSet Research has provided data showing that 16 brokerages have issued ratings for the stock. 1 analysts have rated it as a sell, while 0 advise that it is a overweight. 14 analysts have rated it as a buy and 1 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Strong Buy the stock.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on May 21, 2025 when Deutsche Bank upgraded the stock to “Buy” and issued a price target of $35. Guggenheim downgraded its price target at $23-$20.
The current price level is 1.32%, 18.97%, and 28.99% away from its SMA20, SMA50, and SMA200 respectively, with the ACAD price moving above the 50-day SMA on current market day. Acadia Pharmaceuticals Inc (ACAD) stock is up 1.22% over the week and 3.99% over the past month. Its price is 51.93% year-to-date and 22.13% over the past year.
Its 12-month price target is $24. To reach the target analysts have set, the stock logically needs to grow 19.36 percent from here. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $20, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $32.
Outstanding shares total 167.12M with insiders holding 0.68% of the shares and institutional holders owning 105.60% of the company’s common stock. The company has a return on investment of 28.26% and return on equity of 37.24%. The price to earnings ratio (P/E ratio) amounts to 16.31 while the forward price to earnings ratio is 26.63. The beta has a value of 0.65. Price to book ratio is 4.89 and price to sales ratio is 3.76.
